Pelthos Therapeutics to Participate in the 2025 Wells Fargo Healthcare Conference

Rhea-AI Summary

Pelthos Therapeutics (NYSE American: PTHS), a biopharmaceutical company, announced its participation in the upcoming Wells Fargo Healthcare Conference. CEO Scott Plesha and CFO Frank Knuettel will deliver a presentation on Wednesday, September 3rd, 2025 at 1:30 p.m. ET.

The presentation will be accessible via webcast on the Events and Presentations section of Pelthos' website, with replays available for 90 days following the event. Institutional investors interested in one-on-one meetings should contact their sales representatives.

News Market Reaction – PTHS

-5.03% 1.9x vol

13 alerts

-5.03% Session close to close

+33.6% Peak in 21 hr 12 min

$91.26M Market Cap

1.9x Rel. Volume

In the Sep 2 session, PTHS declined 5.03%, reflecting a notable negative market reaction. Argus tracked a peak move of +33.6% during that session. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility. Trading volume was above average at 1.9x the daily average, suggesting increased trading activity.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Management’s presentation will take place on Wednesday, September 3rd, 2025 at 1:30 pm (ET)

DURHAM, N.C., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company (“Pelthos” or the “Company”) committed to commercializing innovative therapeutic products for high unmet patient needs, today announced that Scott Plesha, CEO, and Frank Knuettel, CFO, will participate in the Wells Fargo Healthcare Conference. Management’s presentation will take place on Wednesday, September 3^rd, 2025 at 1:30 p.m. E.T.

For one-on-one meeting requests please contact your institutional sales representative. A webcast of the presentation will be available on the Events and Presentations pages of Pelthos’ website at https://pelthos.com. Archived replays will be available for 90 days following the event.

About Pelthos Therapeutics
Pelthos Therapeutics is a biopharmaceutical company committed to commercializing innovative, safe, and efficacious therapeutic products to help patients with unmet treatment burdens. The company’s lead product ZELSUVMI™ (berdazimer) topical gel, 10.3%, for the treatment of molluscum contagiosum, was approved by the U.S. Food and Drug Administration in 2024. More information is available at www.pelthos.com. Follow Pelthos on LinkedIn and X.

Contacts

Pelthos Investor Inquiries:
Mike Moyer
Managing Director, LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com

Media:
KWM Communications
Kellie Walsh / Rachel Kessler
pelthos@kwmcommunications.com
(914) 315-6072

FAQ

When is Pelthos Therapeutics (PTHS) presenting at the Wells Fargo Healthcare Conference 2025?

Pelthos Therapeutics will present on Wednesday, September 3rd, 2025 at 1:30 p.m. ET.

Who will represent Pelthos Therapeutics at the Wells Fargo Healthcare Conference?

CEO Scott Plesha and CFO Frank Knuettel will represent Pelthos Therapeutics at the conference.

How can investors access Pelthos Therapeutics' Wells Fargo conference presentation?

The presentation will be available via webcast on Pelthos' website at pelthos.com, with replays available for 90 days after the event.

How can investors schedule one-on-one meetings with Pelthos Therapeutics management?

Investors should contact their institutional sales representatives to request one-on-one meetings with management.